Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer Article / By Mike Echalaz Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer Leia mais »
CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review) Article / By Mike Echalaz CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review) Leia mais »
A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer Article / By Mike Echalaz A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer Leia mais »
Targeting CDK4 and CDK6 in cancer Article / By Mike Echalaz Targeting CDK4 and CDK6 in cancer Leia mais »
Targeting CDK4 and CDK6 in cancer Article / By Mike Echalaz Targeting CDK4 and CDK6 in cancer Leia mais »
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study Article / By Mike Echalaz Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study Leia mais »
Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities Article / By Mike Echalaz Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities Leia mais »
CDK4 and CDK6 kinases: From basic science to cancer therapy Article / By Mike Echalaz CDK4 and CDK6 kinases: From basic science to cancer therapy Leia mais »
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) Article / By Mike Echalaz Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) Leia mais »
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1) Article / By Mike Echalaz Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1) Leia mais »
